DDInter1042 DDInter125
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Asenapine {u} (Compound) binds {v} (Gene) HRH2
Asenapine {u} (Compound) downregulates {v} (Gene) IGFBP2
Asenapine {u} (Compound) causes {v} (Side Effect) Parkinsonism
Asenapine (Compound) resembles Loxapine (Compound)
Asenapine (Compound) binds HRH2 (Gene)
Asenapine (Compound) downregulates IGFBP2 (Gene)
Asenapine (Compound) causes Parkinsonism (Side Effect)